Bristol-Myers Squibb is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company's products are sold worldwide, primarily to wholesalers, specialty distributors, retail pharmacies, hospitals, government entities and the medical profession. The company manufactures products in the United States and Puerto Rico and has manufacturing operations in two foreign countries. The company has products in the following therapeutic classes: hematology, oncology, cardiovascular and immunology. The company's pharmaceutical products include chemically-synthesized or small molecule drugs and products produced from biological processes, called biologics.
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
A director at Bristol Myers Squibb Co sold 25,000 shares at 60.640USD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names...
Bristol-Myers Squibb Company (BMY:USA) currently trades below historical averages relative to UAFRS-based (Uniform) earnings, with a 6.1x Uniform P/E. At these levels, the market is pricing in bearish expectations for the firm, and management may have concerns about their growth opportunities, new product launches, and Opdivo and Yervoy demand Specifically, management may be exaggerating their future growth opportunities, the strength of their balance sheet, and the success of new product launches. Moreover, they may have concerns about trial efficacy and utilization readouts, the potential o...
The independent financial analyst theScreener just slightly lowered the general evaluation of LIFE HEALTHCARE (ZA), active in the Health Care Providers industry. The title has lost a star(s) at the fundamental level and now shows 3 out of 4 stars. Its exposure to market risk remains nonetheless the same and can be still described as defensive. theScreener slightly downgrades the general evaluation to Slightly Positive for the title on account of the lost star(s). As of the analysis date September 24, 2021, the closing price was ZAR 24.15 and its potential was estimated at ZAR 28.95.
WESTAMERICA BANCORP (US), a company active in the Money Center Banks industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date September 24, 2021, the closing price was USD 55.51 and its target price was estimated at USD 48.49.
The general evaluation of WEBSTER FINANCIAL (US), a company active in the Money Center Banks industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date September 24, 2021, the closing price was USD 51.65 and its potential was estimated at USD 60.78.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.